Drug development and the importance of ethnicity: Lessons from heart failure management and implications for hypertension

Current Pharmaceutical Design

Volumn 10, Issue 29, 2004, Pages 3569-3577

  Sosin, Michael D ^a   Bhatia, Gurbir S ^a   Lip, Gregory Y H ^a   Davis, Russell C ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BENDROFLUMETHIAZIDE; BOSENTAN; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; CLONIDINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL; OMAPATRILAT; PLACEBO; PRAZOSIN; SPIRONOLACTONE; VALSARTAN; VERAPAMIL;

AFRICAN CARIBBEAN; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; EPIDEMIOLOGY; ETHNIC GROUP; ETHNOLOGY; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SOUTH ASIA; UNITED KINGDOM; WESTERN HEMISPHERE;

CARDIAC OUTPUT, LOW; CARDIOVASCULAR AGENTS; DRUG DESIGN; HUMANS; HYPERTENSION;

EID: 6344222218     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382783     Document Type: Review

References (99)

1. Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life. Eur Heart J 2002; 23; 1867-1876.
2. Sutton GC. Epidemiological aspects of heart failure. Am Heart J 1990; 120: 1538-40.
3. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJV. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4: 361-371.
4. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993; 126: 1042-7.
5. Bonneaux L, Barendregt JJ, Meeter K, Bonsel GJ, Van der Maas PJ. Estimating clinical morbidity due to ischaemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994; 84: 20-8.
6. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-3072.
7. McKee PA, Castelli WP, McNamara WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6.
8. Cowie MR, Wood DA, Coats JS, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure: a population based study. Eur Heart J 1999; 20: 421-8.
9. Data fact sheet: congestive heart failure in the United States: a new epidemic. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1996.
10. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340: 609-616.
11. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville, Md: National Center for Health Statistics; 1995.
12. Rathore SS, Foody JM, Wang Y, Smith GL, Herrin J, Masoudi FA, et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA 2003; 289: 2517-2524.
13. Lip G, Zarifis J, Beevers DG. Acute admissions with heart failure to a district general hospital serving a multiracial population. Int J Clin Pract 1997; 51: 223-7.
14. Chaturvedi N. Ethnic differences in cardiovascular disease. Heart 2003; 89: 681-686.
15. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348: 1647-1655.
16. Coughlin SS, Labenberg JR, Tefft MC. Black-white differences in idiopathic dilated cardiomyopathy: the Washington DC dilated Cardiomyopathy Study. Epidemiology 1993; 4: 165-172.
17. Coughlin SS, Neaton JD, Sengupta A, Kuller LH. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1994; 139: 166-72.
18. Hypertension Detection and Follow Up Program Cooperative Group. Race, education and prevalence of hypertension. Am J Epidemiol 1977; 106: 351-61.
19. Cooper ES, Kuller LH, Saunders E, Martinez-Maldonado M, Caplan LR, Yatsu FM, et al. Cardiovascular diseases and stroke in African-Americans and other racial minorities in the United States: a statement of health professionals. Circulation 1991; 83: 1462-1480.
20. Stamler J, Rhomberg P, Schonberger JA, Shekelle RB, Dyer A, Shekelle S, et al. Multivariate analysis of the relationship of seven variables to blood pressure. Journal of Chronic Disease 1975; 28: 527-48.
21. Meade TW, Brosovic M, Chakraborti R, Haines AP, North WRS, Stirling Y. Ethnic group comparisons of variables associated with ischaemic heart disease. Br Heart J 1978; 40: 789-95.
22. Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among US blacks, or is severe hypertension more common? Ann Epidemiol 1996; 6: 173-180.
23. Mayet J, Shahi M, Foale RA, Poulter NR, Sever PS, McG Thom SA. Racial differences in cardiac structure and function in essential hypertension. BMJ 1994; 308: 1011-1014.
24. Sullivan JM: Salt-sensitivity: Definition, conception, methodology, and long-term issues. Hypertension 1991; 17(suppl 1): 161-168.
25. Light KC, Sherwood A, Turner JR. High cardiovascular reactivity to stress: A predictor of later hypertension development. In: Turner JR, Sherwood A, Light KC, eds. Individual differences in cardiovascular response to stress. New York, NY: Plenum Press; 1992; 281-293.
26. Thomas J, Semenya K, Thomas CB, Thomas DJ, Neser WB, Pearson TA, et al. Precursors of hypertension in black compared to white medical students. J Chronic Dis 1987; 40(7): 721-7.
27. Murphy MB, Nelson KS, Oliner CM, Elliot WJ. Higher nocturnal blood pressure in normal and hypertensive blacks compared with whites. Circulation 1988; 48: 2268A.
28. Harshfield GA, Hwang C, Grim C. The circadian variation of blood pressure in blacks: influence of age, gender and activity. J Hum Hypertens 1990; 4: 43-7.
29. Harshfield GA, Alpert BS, Willey ES, Somes GW, Murphy JK, Dupaul LM. Race and gender influence ambulatory blood pressure patterns of adolescents. Hypertension 1989; 14: 598-603.
30. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hypertens 2002; 15: 111-118.
31. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohormonal axis in congestive heart failure. Ann Intern Med 1984; 101: 370-377.
32. Pouleur H, Benedict CR, Rousseau MR. Neurohormones in patients with ischemic left ventricular dysfunction. Crdiovasc Drugs Ther 1994; 8: 313-317.
33. Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 1987; 114: 148-152.
34. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector TS, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(Suppl VI): VI5-VI16.
35. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension 1993; 22: 801-805.
36. Rutledge DR, Cardozo L, Steinberg JD. Racial differences in drug response: isoproterenol effects on heart rate in healthy males. Pharm Res 1989; 6: 182-185.
37. Dimsdale JE, Graham RM, Ziegler MG, Zusman RM, Berry CC. Age, race, diagnosis, and sodium effects on the pressor response to infused norepinephrine. Hypertension 1987; 10: 564-569.
38. Duey WJ, Bassett DR Jr, Walker AJ, Torok DJ, Howley ET, Ely D, et al. Cardiovascular and plasma catecholamine response to static exercise in normotensive blacks and whites. Ethn Health 1997; 2: 127-136.
39. Sherwood A, Hinderliter AL. Responsiveness to alpha- and beta-adrenergic receptor agonists: effect of race in borderline hypertensive compared to normotensive men. Am J Hypertens 1993; 6: 630-635.
40. Mills PJ, Dimsdale JE, Ziegler MG, Nelesen RA. Racial differences in epinephrine and beta 2-adrenergic receptors. Hypertension 1995; 25: 88-91.
41. Sudhir K, Forman A, Yi SL, Sorof J, Schmidlin O, Sebastian A, et al. Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. Hypertension 1997; 29: 1083-1090.
42. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
43. Jilma B, Szalay T, Dirnberger E, Eichler HG, Stohlawetz P, Schwarzinger I, et al. Effects of endothelin-1 on circulating adhesion molecules in man. Eur J Clin Invest 1997; 27: 850-856.
44. Krejcy K, Eichler HG, Jilma B, Kapiotis S, Wolzt M, Zanaschka G, et al. Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Can J Physiol Pharmacol 1996; 74: 9-14.
45. Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Colch) 1990; 78: 261-264.
46. Kohno M, Yasunari K, Murakawa K, Yokokawa K, Horio T, Fukui T, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88: 614-618.
47. Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15: 493-496.
48. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4: 303-308.
49. Evans RR, Phillips BG, Singh G, Bauman JL, Gulati A. Racial and gender differences in endothelin-1. Am J Cardiol 1996; 78: 486-488.
50. Treiber FA, Jackson RW, Davis H, Pollock J, Kapuku G, Mensah GA, et al. Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males. Hypertension 2000; 35: 722-5.
51. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996; 28: 652-655.
52. Ergul A, Shoemaker K, Puett D, Tackett FL. Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther 1998; 285: 511-517.
53. Ergul A, Tackett RL, Puett D. Distribution of endothelin receptors in saphenous veins of African Americans: Implications of racial differences. J Cardiovasc Pharmacol 1999; 34: 327-332.
54. Barton M, Vos I, Shaw S, Boer P, D'Uscio LV, Gröne H-J, et al. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: Mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 2000: 11; 835-846.
55. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697.
56. Schrier RW, Abraham WT. Hormones and haemodynamics in heart failure. N Engl J Med 1999; 341: 577-585.
57. Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor in essential hypertension: more evidence. Am J Med 1973; 55: 295.
58. Rowlands DB, DeGiovanni J, McLeay RAB, Watson RDS, Stallard TJ, Littler WA. Cardiovascular response in black and white hypertensives. Hypertension 1982; 4: 817-20.
59. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5: 178-87.
60. Mahgoub MA, Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell Biochem 1998; 180: 59-64.
61. Duan J, Zhang HY, Adkins SD, Ren BH, Norby FL, Zhang X, et al. Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: role of Akt and RhoA. Am J Physiol Endocrinol Metab 2003; 284: E366-76.
62. Abate N, Chandalia M. The impact of ethnicity on type 2 diabetes. J Diabetes Complications 2003; 17: 39-58.
63. Makin AJ, Silverman SH, Lip GY. Ethnicity and peripheral vascular disease. Int J Clin Pract 2002; 56: 645-8.
64. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study, XII. Differences between Asian, Afro-Caribbean and White Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabetic Medicine 1994; 11: 670-677.
65. Davis RC, Hobbs FDR, Kenkre JE, Roalfe AK, Hare R, Lancashire RJ, et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community-based epidemiological study. BMJ 2002; 325: 1156-8.
66. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989; 117: 211-21.
67. Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92: 3436-44.
68. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983; 68: 785-95.
69. Barakat K, Wells Z, Ramdhany S, Mills PG, Timmis AD. Bangladeshi patients present with non-classic features of acute myocardial infarction and are treated less aggressively in east London, UK. Heart 2003; 89: 276-279.
70. Feder G, Crook AM, Magee P, Banerjee S, Timmis AD, Hemingway H. Ethnic differences in invasive management of coronary disease: prospective cohort study of patients undergoing angiography. BMJ 2002; 324: 511-516.
71. Lip GYH, Rathore VS, Katira R, Watson RD, Singh SP. Do Indo-Asians have smaller coronary arteries? Postgrad Med J 1999; 75: 463-6.
72. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
73. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-921.
74. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-1713.
75. Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992; 5: 37-44.
76. Cubeddu LX, Aranda J, Singh B, Klein M, Brachfeld J, Freis E, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA 1986; 256: 2214-2221.
77. Freudenberger R, Kalman J, Mannino M, Buchholz-Varley C, Ocampo O, Kukin M. Effect of race in the response to metoprolol in patients with congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol 1997; 80: 1372-1374.
78. Domanski MJ. Beta-blocker evaluation of survival trial (BEST). J Am Coll Cardiol 2000; 35: Suppl A: 202A-203A. Abstract.
79. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344: 1358-1365.
80. Weir MR, Gray JM, Pater R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients: The trandalopril multicentre study group. Hypertension 1995; 26: 124-130.
81. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351-7.
82. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 1990; 66: 40D-44D.
83. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). 2001. ACC Web site. Available at: http: /www.acc.org/clinical/guidelines/failure/hf_index.htm
84. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
85. Julius S, Alderman MH, Beevers G, Dahlof B, Devereux RB, Douglas JG, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004; 43: 1047-1055.
86. Patel JKV, Leaback R, on behalf of the POSATIV investigators. Patients of Southern Asian descent treated with valsartan (POSATIV) study. Brit J Cardiol 2002; 9: 351-354.
87. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
88. Pitt B, Zannad F, Remm WJ, Cody R, Castaigne A, Perez A, et al. for the Randomised Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
89. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148-1155.
90. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195-7.
91. Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001; 38: 1342-1348.
92. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620.
93. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-926.
94. Messerli FH, Nussberger J. Vasopeptidase inhibition and angiooedema. Lancet 2000; 356: 608-9.
95. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999; 48: 861-5.
96. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002; 8: 128-135.
97. Amudha K, Wong LP, Choy AM, Lang CC. Ethnicity and drug therapy for hypertension. Curr Pharm Design 2003; 9(21): 1691-701.
98. Carbonin P, Zuccala G, Marzetti E, Lo Monaco MR. Coronary risk factors in the elderly: their interactions and treatment. Curr Pharm Design 2003; 9(29): 2465-78.
99. MacFadyen RJ, Lip GY, Davis R. Hypertension to heart failure: new developmental strategies do not cross a clinical and therapeutic divide. Curr Pharm Design 2003; 9(21): 1665-78.